CD274 and head and neck squamous cell carcinoma: Indeed, KESTREL did not demonstrate the superiority of durvalumab or durvalumab plus tremelimumab compared with the standard of care (EXTREME regimen) in terms of OS as first-line treatment in advanced HNSCC patients with tumors expressing a high level of PD-L1.